Do you routinely use risk assessment scores (e.g., the Khorana score) to assess the risk of venous thromboembolism and consideration of prophylactic anticoagulation in ambulatory cancer patients undergoing / about to undergo treatment?

What factors other than the Khorana score influence your decision regarding prophylactic anticoagulation in these patients? If prescribing an agent, what specific DOAC or LMWH do you use?

Please select the option that best describes you:

Do you routinely use risk assessment scores (e.g., the Khorana score) to assess the risk of venous thromboembolism and consideration of prophylactic anticoagulation in ambulatory cancer patients undergoing / about to undergo treatment?

Related Questions